What Determines the Retinal Concentration of an Intravitreally Injected Antibody? New Insights Using a 3-Compartment Semi-Mechanistic Pharmacokinetic Model

Norman A. Mazer(Roche (Switzerland)), Kapil Gadkar(Sea Turtle Conservancy), Philip K. Maini(University of Oxford), Laurence A. Hutton-Smith(Mathematical Institute of the Slovak Academy of Sciences), Eamonn A. Gaffney(University of Oxford), Helen M. Byrne(University of Oxford)
Investigative Ophthalmology & Visual Science
June 23, 2017
Cited by 0

Related Papers

Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
|Science Translational Medicine|2014|373
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
|Cell|2022|327
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
|Science Translational Medicine|2013|267
A TREM2-activating antibody with a blood–brain barrier transport vehicle enhances microglial metabolism in Alzheimer’s disease models
|Nature Neuroscience|2023|227
Iterative approach to model identification of biological networks
|BMC Bioinformatics|2005|157